The trial comprised an initial safety run-in using abituzumab doses up to 1000 mg combined with a standard of care ( SoC : cetuximab plus irinotecan ) and a phase II part in which patients were randomised 1 : 1 : 1 to receive abituzumab 500 mg ( arm A ) or 1000 mg ( arm B ) every 2 weeks combined with SoC , or SoC alone ( arm C ) .